Citius Oncology (CTOR) Other Accumulated Expenses (2023 - 2026)

Citius Oncology's Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 66.37% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (up 66.37% YoY), while the FY2025 annual figure was $9.5 million, up 1515.77% from the prior year.
• Other Accumulated Expenses was $8.2 million for Q1 2026 at Citius Oncology, down from $11.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $19.5 million in Q3 2023 to a low of $344875.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $5.6 million across 4 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses plunged 96.98% in 2024, then surged 1515.77% in 2025.
• A 4-year view of Other Accumulated Expenses shows it stood at $344875.0 in 2023, then jumped by 739.82% to $2.9 million in 2024, then soared by 296.87% to $11.5 million in 2025, then declined by 28.48% to $8.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $8.2 million (Q1 2026), $11.5 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.